Warfarin Sensitivity Genotyping
Polymorphisms and Warfarin Sensitivity
August 2008
A second more deleterious allele designated as CYP2C9*3 has a substitution of a leucine for isoleucine caused by a change in nucleotide at 1075 of an adenine to a cytosine. Enzymatic activity is reduced to approximately 10% of the normal the *1 wild type with no polymorphisms. The allelic frequency once again is population-dependent with the highest frequencies again found in Northern European white populations of between 6% and 10% frequency.
So these are common changes in the genes that cause frequent changes in the amount of activity in the CYP2C9 protein.
Polymorphisms and Warfarin Sensitivity |
Jump to section:
- Introduction
- Warfarin
- Warfarin Anticoagulation
- Warfarin
- Warfarin Monitoring
- Therapeutic Graph
- INR Variability in a 74 Year-old Male
- Warfarin and Bleeding Events
- Warfarin Metabolism
- Polymorphisms and Warfarin Sensitivity
- Polymorphisms and Warfarin Sensitivity
- Summary of Polymorphisms and Warfarin Pharmacokinetics5
- CYP2C9 Association Study
- PGx-Guided Warfarin Dosing7
- Warfarin Pharmacodynamics
- Polymorphisms and Warfarin Sensitivity
- VKORC1 Promoter Polymorphism6
- CYP2C9 and VKORC1 Interaction8
- Genotype-guided Warfarin Dosing9
- Genotype-guided Dosing
- Summary
- Orthopedic Algorithm10
- Significant Warfarin Drug Interactions
- Differential Effect of Drugs
- Patient Case: Rapidly Increasing INR
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document